Clinical Trial Update: Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease [Phase 2]

View source ↗

Summary

A Phase 2 study of Obeldesivir for postexposure prophylaxis of filovirus diseases has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Filovirus Disease

Drugs mentioned

• Obeldesivir (Obeldesivir)

Snippet

Sponsor: Gilead Sciences | Conditions: Filovirus Disease, Postexposure Prophylaxis for Filovirus Disease | Phase 2 | Status: WITHDRAWN